CD274 and neoplasm: However, a majority of cancer patients do not respond to anti-programmed cell death protein (ligand) 1 (anti-PD(L)-1) therapy due to multiple immunosuppressive mechanisms in the tumor microenvironment (TME), including dysfunctional T cells and a lack of T cell infiltration or tumor recognition by T cells [7].